[1] Liu J, Heikkila¨ P, Meng Q, Kahri A.I, Tikkanen M.J, Voutilainen R. Expression of low and high density lipoprotein receptor genes in human adrenals. Eur J Endocrinol 2000; 142: 677-682.
[2] Capponi A.M. Regulation of cholesterol supply for mineralocorticoid biosynthesis. Endocrinol & Metab 2002; 13: 118-121. doi: 10.1016/S1043-2760(01)00538-0.
[3] Miler W.L. Steroid hormone synthesis in mitochondria. Mol. Cell. Endocrinol 2013; 379 :62-73. doi: 10.1016/j.mce.2013.04.014.
[4] Waterham H.R, Koster J, Romeijn G.J, Hennekam R.C, Vreken P, Andersson H.C, FitzPatrick D.R, Kelley R.I, Wanders R.J. Mutations in the 3-hydroxysterol 24-reductase gene cause desmosterolosis, an autosomal recessive disorder of cholesterol biosynthesis. Am J Hum Genet 2001; 69: 685–694. doi: 10.1086/323473.
[5] Clark B.J, Stocco D.M. StAR-A tissue specific acute mediator of steroidogenesis. Trends Endocrinol Metab. 1996; 7(7): 227–233. doi: 10.1016/S1043-2760(96)00114-2.
[6] Funder J.W. The genetics of primary aldosteronism. Science 2011; 331: 685–686. doi: 10.1126/science.1202887.
[7] Rossi G.P, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, et al. A prospective study of the prevalence of primary aldosteronism in 1125 hypertensive patients. J. Am. Coll. Cardiol 2006; 48: 2293–2300.
[8] Williams J.S, Williams G.H, Raji A, Jeunemaitre X, Brown N.J, Hopkins P.N, Conlin P.R, Prevalence of primary hyperaldosteronism in mild to moderate hypertension without hypokalaemia. J. Hum. Hypertens 2006; 20: 129–136. doi: 10.1038/sj.jhh.1001948.
[9] Nakamura Y, Felizola SJ, Satoh F, Konosu-Fukaya S, Sasano H. Dissecting the molecular pathways of primary aldosteronism. Pathol Int. 2014; 64: 482–489. doi: 10.1111/pin.12200.
[10] Neville AM, O’Hare MJ. The Human Adrenal Cortex: Pathology and Biology-An Integrated Approach. Berlin, Germany: Springer-Verlag; 1982.
[11] Choi M, Scholl UI, Yue P, Bjorklund P, Zhao B, Nelson-Williams C, Ji W. Cho Y. Patel A, Men C.J, et al. Kt channel mutations in adrenal aldosteroneproducing adenomas and hereditary hypertension. Science, 2011; 331: 768–772. doi: 10.1126/science.1198785.
[12] Beuschlein F, Boulkroun S, Osswald A, Wieland T, Nielsen H.N, Lichtenauer, UD, Penton D, Schack V.R, Amar L, Fischer E, et al. Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nat Genet. 2013; 45: 440–444, 444e1. doi: 10.1038/ng.2550.
[13] Azizan E.A, Poulsen H, Tuluc P, Zhou J, Clausen M.V, Lieb A, Maniero C, Garg S, Bochukova E.G, Zhao W, et al. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. Nat Genet. 2013; 45: 1055–1060. doi: 10.1038/ng.2716.
[14] Berthon A, Drelon C, Ragazzon B, Boulkroun S, Tissier F, Amar L, Couterie B.S, Zennaro M.C, Zennaro M.C, et al. WNT/β-catenin signalling is activated in aldosterone-producing adenomas and controls aldosterone production. Hum Mol Genet. 2014; 23: 889–905. doi: 10.1093/hmg/ddt484.
[15] Kitamoto T, Suematsu S, Yamazaki Y, Nakamura Y, Sasano H, Matsuzawa Y, Saito J, Omura M, Nishikawa T. Clinical and steroidogenic characteristics of aldosterone-producing adenomas with ATPase or CACNA1D gene mutations. J Clin Endocinol Metab. 2016; 101: 494 –503. doi: 10.1210/jc.2015-3284.
[16] Lenzini L, Rossitto G, Maiolino G, Leitizia C, Funder J.W, Rossi, G.P. A meta-analysis of somatic KCNJ5 K+ channel mutations in 1636 patients with an aldosterone-producing adenoma. J Clin Endocinol Metab. 2015; 100: E1089-E1095. doi: 10.1210/jc.2015-2149.
[17] Yamazaki Y, Omata K, Tezuka Y, Ono Y, Morimoto R, Adachi Y, Ise K, Nakamura Y, Gomez-sanchez C.E, Shibahara Y, et al. Tumor cell subtypes based on the intracellular hormonal activity in KCNJ5-mutated aldosterone-producing adenoma. Hypertension. 2018; 72: 632-640. doi: 10.1161/hypertensionaha.118.10907.
[18] Nishikawa T, Omura M, Satoh F, Shibata H, Takahashi K, Tamura N, Tanabe A. Task Force Committee on Primary Aldosteronism, The Japan Endocrine Society. Guidelines for the diagnosis and treatment of primary aldosteronism--the Japan Endocrine Society 2009. Endocr J. 2011;58(9):711-21. doi: 10.1507/endocrj.EJ11-0133.
[19] Budwit-Novotny, D.A, McCarty, K.S, Cox, E.B, Soper, J.T, Mutch, D.G, Creasman,W.T, Flowers J.L, McCarty Jr K.S. Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res, 1986; 46 (10): 5419–5425.
[20] Konosu-Fukaya S, Nakamura Y, Satoh F, Felizola S.J, Maekawa T, Ono Y, Morimoto R, Ise K, Takeda K, Katsu K, et al. 3β-hydroxysteroid dehydrogenase isoforms in human aldosterone-producing adenoma. Molecular and Cellular Endocrinology, 2015; 408: 205–212. doi: 10.1016/j.mce.2014.10.008.
[21] Son H.H, Moon J.Y, Seo H.S, Kim H.H, Chung B.C, Choi M.H. High-temperature GC-MS-based serum cholesterol signatures may reveal sex differences in vasospastic angina. J Lipid Res. 2014; 55: 155-162.
[22] Kempen H.J, Glatz J.F, Gevers Leuven J.A, van der Voort H.A, Katan M.B. Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans. J Lipid Res. 1988; 29(9): 1149– 1155. doi: 10.1016/S0022-2275(20)38456-X.
[23] Bertrand Cariou, Wieneke Dijk. EGF-A peptides: A promising strategy for PCSK9 inhibition. Atheroscler 2020; 292: 204-206.
[24] Borkowski A.J, Levin S, Delcroix C, Mahler A, Verhas V. Blood cholesterol and hydrocortisone production in man: quantitative aspects of the utilization of circulating cholesterol by the adrenals at rest and under adrenocorticotropin stimulation. J Clin Invest. 1967; 46(5): 797–811. doi: 10.1172/JCI105580.
[25] Brown M.S, Kovanen P.T, Goldstein J.L. Receptor-mediated uptake of lipoprotein-cholesterol and its utilization for steroid synthesis in the adrenal cortex. Recent Prog Horm Res. 1979; 35: 215–257. doi: 10.1016/B978-0-12-571135-7.50009-6.
[26] Connelly M.A, Williams D.L. SR-BI and cholesterol uptake into steroidogenic cells. Trends Endocrinol Metab. 2003; 14(10): 467–472. doi: 10.1016/j.tem.2003.10.002.
[27] Higashijima M, Nawata H, Kato K, Ibayashi H. Studies on lipoprotein and adrenal steroidogenesis: I. Roles of low density lipoprotein- and high density lipoprotein-cholesterol in steroid production in cultured human adrenocortical cells. Endocrinologia Japonica 1987(34) 635–645. doi: 10.1507/endocrj1954.34.635.
[28] Azhar S, Reaven E: Scavenger receptor class BI and selective cholesteryl ester uptake: partners in the regulation of steroidogenesis. Mol Cell Endocrinol 2002; 195: 1-26. doi: 10.1016/S0303-7207(02)00222-8.
[29] Azhar S, Leers-Sucheta S, Reaven E: Cholesterol uptake in adrenal and gonadal tissues: the SR-BI and 'selective' pathway connection. Front Biosc 2003; s998-1029.
[30] Krieger, M. Charting the fate of the ‘good cholesterol’: identification and characterization of the high-density lipoprotein receptor SR-BI. Annu Rev Biochem 1999; 68: 523–558. doi: 10.1146/annurev.biochem.68.1.523.
[31] Connelly M.A, Williams, D.L. Scavenger receptor BI (SR-BI) and cholesterol trafficking. Curr Opin Lipidol 1999; 10: 329–339. doi: 10.1016/j.tem.2003.10.002.
[32] London E, Wassif C.A, Horvath A, Tatsi C, Angelousi A, Karageorgiadis A.S, Porter F.D, Stratakis C.A. Cholesterol biosynthesis and trafficking in cortisol-producing lesions of the adrenal cortex. J Clin Endocrinol Metab 2015; 100(10): 3660–3667. doi: 10.1210/jc.2015-2212.
[33] Yamada M, Nakajima Y, Taguchi R, Okamura T, Ishii S, Tomaru T, Ozawa A, Shibusawa N, Yoshino S, Toki A, et al. KCNJ5 mutaions in aldosterone-and cortisol-co-secreting adrenal adenomas. Endocr J 2012; 59(8): 735-741. doi: 10.1507/endocrj.EJ12-0247.
[34] Liu J, Heikkila P, Meng Q, Kahri A, Tikkanen M and Voutilainen R. Expression of low and high density lipoprotein receptor genes in human adrenals. Eur J endocrinol 2000; 142: 677–682.
[35] Inoue K, Yamazaki Y, Kitamoto T, Hirose R, Saito J, Omura M, Sasano H, and Nishikawa T. Aldosterone suppression by dexamethasone in patients with KCNJ5-mutated aldosterone-producing adenoma. J Clin Endocrinol Metab 2018; 103(9): 3477–3485.